Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1505-1510

  Mukai, Masaya ^a   Tajima, Takayuki ^b   Sato, Shinkichi ^c   Ninomiya, Hiromi ^c   Wakui, Kanako ^c   Komatsu, Nobukazu ^c   Tsuchiya, Kazutoshi ^c   Nakasaki, Hisao ^c   Makuuchi, Hiroyasu ^b  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Chemosensitivity; Dihydropyrimidine dehydrogenase; Gastric cancer; Isolated tumor cells; Micrometastasis; Occult neoplastic cells; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER STAGING; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; STOMACH TUMOR; SURVIVAL; TUMOR RECURRENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE;

EID: 33644681173     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1505     Document Type: Article

References (37)

1. Journal of Health and Welfare Statistics, Health and Welfare Statistics Association, Tokyo 51: 46-49, 2004.
2. National Institutes of Health Consensus Development Panel. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93: 979-989, 2001.
3. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn H-J: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19: 3817-3827, 2001. (Pubitemid 32880060)
4. Japanese Classification of Gastric Carcinoma. Japanese Research Society for Gastric Cancer. 1st English edition. Kanehara & Co., Ltd., Tokyo, 1995.
5. Multi-Institutional Registry of Large Bowel Cancer in Japan. Vol. 23. Cases treated in 1994. Japanese Society for Cancer of the Colon and Rectum, Tokyo, 2002.
6. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes' C colorectal cancer. Oncol Rep 10: 1165-1169, 2003.
7. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes' B colorectal cancer. Oncol Rep 10: 1177-1181, 2003.
8. Mukai M, Sato S, Nishida T, Komatsu N, Shiba K, Nakasaki H and Makuuchi H: Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer. Oncol Rep 10: 1753-1758, 2003.
9. Mukai M, Sato S, Nakasaki H, Saito Y, Nishiumi N, Iwasaki M, Tokuda Y, Ogoshi K, Inoue H and Makuuchi H: Occult neoplastic cells in the lymph node sinuses and recurrence of primary breast, lung, esophageal and gastric cancer. Oncol Rep 11: 81-84, 2004.
10. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi M: Accuracy of criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis. Oncol Rep 12: 59-62, 2004.
11. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Accuracy of criteria for predicting recurrence and metastasis in stage II and III gastric cancer with lymph node metastasis. Oncol Rep 12: 63-66, 2004.
12. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting the recurrence/metastasis of stage II and III breast cancer with lymph node metastasis. Oncol Rep 12: 303-306, 2004.
13. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting the recurrence/metastasis of stage I and II breast cancer without lymph node metastasis. Oncol Rep 12: 745-748, 2004.
14. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of stage II/Dukes' B colorectal cancer without lymph node metastasis. Oncol Rep 12: 1127-1130, 2004.
15. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of stage III/Dukes' C colorectal cancer with lymph node metastasis. Oncol Rep 12: 1301-1304, 2004.
16. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of Dukes' A primary colorectal cancer with or without proper muscle invasion. Oncol Rep 12: 1305-1308, 2004.
17. Mukai M: Occult neoplastic cells and malignant micro-aggregates in lymph node sinuses: review and hypothesis. Oncol Rep 14: 173-175, 2005.
18. TNM classification of malignant tumours. 6th edition. John Wiley & Sons, Inc., New York, 2002.
19. Hsu C-H, Yeh K-H, Chen L-T, Liu JM, Jan C-M, Lin J-T, Chen Y-C and Cheng A-L: Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. Oncology 54: 275-280, 1997.
20. Iwamoto S, Kimoto M, Mure T, Onuma E, Yamamoto Y, Iki K, Yoshida K, Tadaoka Y, Majima T, Kawasaki S, Kubozoe T and Tsunoda T: Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer. Jpn J Cancer Chemother 25: 541-546, 1998.
21. Chen J-S, Liu H-E, Wang C-H, Yang T-S, Wang H-M, Liau C-T, Chang W-C and Lin Y-C: Weekly 24-H infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. Anticancer Drugs 10: 355-359, 1999.
22. Enjoji A and the Nagasaki Digestive Organ Cancer Chemotherapy Study Group: Combination chemotherapy of 5-fluorouracil and low-dose Cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan. Anticancer Res 22: 1135-1140, 2002.
23. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T and the S-1 Gastrointestinal Cancer Study Group: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57: 202-210, 1999. (Pubitemid 29481693)
24. Koizumi W, Kurihara M, Nakano S and Hasagawa K for the S-1 Cooperative Gastric Cancer Study Group: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000.
25. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG and Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
26. De Gramont A, Bosset J-F, Milan C, Rougier P, Bouché O, Etienne P-L, Morvan F, Louvet C, Guillot T, François E and Bedenne L: Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 15: 808-815, 1997. (Pubitemid 27074252)
27. Berger SH and Hakala MT: Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 25: 303-309, 1984. (Pubitemid 14173339)
28. Okabe H, Tsujimoto H and Fukushima M: Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and application to sensitivity-study of 5-fluorouracil. Oncol Rep 4: 685-690, 1997. (Pubitemid 27286971)
29. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Kitayama J, Tsuruo T and Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000. (Pubitemid 30215157)
30. Takenoue T, Kitayama J, Takei Y, Umetani N, Matsuda K, Nita ME, Hatano K, Tsuruo T and Nagawa H: Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann Oncol 11: 273-279, 2000. (Pubitemid 30214663)
31. Kamoshida S, Shiogama K, Matsuoka H, Matsuyama A, Shimomura R, Inada K, Maruta M and Tsutsumi Y: Immunohistochemical demonstration of dihydropyrimidine dehydrogenase in normal and cancerous tissues. Acta Histochem Cytochem 36: 471-479, 2003. (Pubitemid 37433065)
32. Nakane PK and Pierce GB: Enzyme-labeled antibodies: preparation and application for localization of antigens. J Histochem Cytochem 14: 929-931, 1966.
33. Nakane PK and Pierce GB: Enzyme-labeled antibody for the light and electron microscopic localization of tissue antigens. J Cell Biol 33: 307-318, 1967.
34. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1165-1169, 2005.
35. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1171-1176, 2005.
36. Feinstein AR, Sosin DM and Wells CK: The Will Rogers phenomenon: stage migration and new techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608, 1985. (Pubitemid 15062653)
37. Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GL and Bruijn JA: Surgical/pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13: 19-25, 1995. Organization